ABSTRACT
Background Younger-onset dementia (YOD) can be challenging to diagnose due to its younger age of onset, heterogeneous aetiologies and broad range of presentations. Misdiagnosis is common with psychiatric conditions often diagnosed initially and diagnostic delay of five years is common. More information is needed to better understand and diagnose YOD, including the nature of symptom onset, progression of the disease, the relationship between cognition and functional outcomes for patients and carers, imaging changes and novel biomarkers. This paper reports on the background behind the “Investigating the clinical utility of biomarkers and other novel tests in younger-onset neurocognitive disorders”, the BeYOND study, and its methodology.
Methods BeYOND is a clinically-oriented “real-world” longitudinal study that follows younger people presenting with an onset of neuropsychiatric symptoms ≤ 65 years of age. We aim to collect information on participants’ cognition, neuroimaging, mental health, and blood and cerebrospinal fluid (CSF) biomarkers at 18-month time-points over 3 years. We also aim to collect information regarding the experience of carers and/or family of participants.
Conclusion Serial assessment of symptomatology, cognition, imaging, and blood and CSF biomarkers will be correlated with eventual diagnosis to determine the usefulness of these measures in determining a confident diagnosis. In addition, repeat measurements of the mental health and well-being of the participant and that of their carers/family while they traverse their diagnostic journey will provide important information about service provision and how they can be better supported.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
This was not registered because this is a study in a clinical real world setting and not an interventional trial.
Funding Statement
Samantha M Loi was supported by the National Health and Medical Research Council Early Career Fellowship (GNT1138968) and the Yulgilbar Alzheimers Research Program.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This project was approved by the local hospital human research ethics committee, the Royal Melbourne Hospital by Professor Peter Colman on behalf of the Royal Melbourne Hospital/Melbourne Health, Human Research Ethics Committee, HREC/48030/MH-2018 (local reference number MH 2018.371),where the project is based. Ethics approval was given on 12 February 2019. The ethical approval form can be submitted too if requested.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Not applicable currently
